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Abstract 
Background: The liver‑stage anti‑malarial activity of primaquine and other 8‑aminoquinoline molecules has been 
linked to bio‑activation through CYP 2D6 metabolism. Factors such as CYP 2D6 poor metabolizer status and/or co‑
administration of drugs that inhibit/interact with CYP 2D6 could alter the pharmacological properties of primaquine.
Methods: In the present study, the inhibitory potential of the selective serotonin reuptake inhibitor (SSRI) and sero‑
tonin norepinephrine reuptake inhibitor (SNRI) classes of antidepressants for CYP 2D6‑mediated primaquine metabo‑
lism was assessed using in vitro drug metabolism and in vivo pharmacological assays.
Results: The SSRI/SNRI classes of drug displayed a range of inhibitory activities on CYP 2D6‑mediated metabolism 
of primaquine in vitro (IC50 1–94 μM). Fluoxetine and paroxetine were the most potent inhibitors (IC50 ~1 µM) of CYP 
2D6‑mediated primaquine metabolism, while desvenlafaxine was the least potent (IC50 ~94 µM). The most potent 
CYP 2D6 inhibitor, fluoxetine, was chosen to investigate the potential pharmacological consequences of co‑adminis‑
tration with primaquine in vivo. The pharmacokinetics of a CYP 2D6‑dependent primaquine metabolite were altered 
upon co‑administration with fluoxetine. Additionally, in a mouse malaria model, co‑administration of fluoxetine with 
primaquine reduced primaquine anti‑malarial efficacy.
Conclusions: These results are the first from controlled pre‑clinical experiments that indicate that primaquine phar‑
macological properties can be modulated upon co‑incubation/administration with drugs that are known to interact 
with CYP 2D6. These results highlight the potential for CYP 2D6‑mediated drug–drug interactions with primaquine 
and indicate that the SSRI/SNRI antidepressants could be used as probe molecules to address the primaquine‑CYP 
2D6 DDI link in clinical studies. Additionally, CYP 2D6‑mediated drug–drug interactions can be considered when 
examining the possible causes of human primaquine therapy failures.
Keywords: Primaquine, Antimalarial, Drug metabolism, Pharmacokinetics, CYP 2D6, Relapsing malaria, Drug–drug 
interactions
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Open Access
Malaria Journal
*Correspondence:  sean.r.marcsisin.mil@mail.mil; marcsisin.s@gmail.com 
Military Malaria Research Program, Experimental Therapeutics Branch, 
Walter Reed Army Institute of Research, 503 Robert Grant Ave, Silver 
Spring, MD 20910, USA
Page 2 of 10Jin et al. Malar J  (2016) 15:280 
Background
Malaria is one of the most common parasitic infections 
that negatively impacts global health and economic sta-
bility. Despite years of effort to control malaria, and 
recent efforts towards malaria eradication, malaria 
remains a global health threat [1–3]. Primaquine, an 
8-aminoquinoline (8AQ) derivative, is the only drug 
licensed for the treatment of relapsing species of malaria 
(Plasmodium vivax and Plasmodium ovale) and has 
gametocytocidal activity which may reduce transmission 
of all parasites that cause human malaria. Despite the 
importance of primaquine in malaria treatment efforts, 
the mechanism of primaquine efficacy and haemolytic 
toxicity are not completely understood [4]. Recently, a 
series of studies indicated that primaquine is a pro-drug 
that is converted to an active metabolite(s) via hepatic 
metabolism [5–13]. CYP 2D6 and MAO-A are the key 
enzymes associated with primaquine metabolism, how-
ever, primaquine’s anti-malarial activity is dependent on 
CYP 2D6-mediated activation [6, 7, 12, 14, 15]. These 
recent series of discoveries are problematic for pri-
maquine usage as human CYP 2D6 is highly polymorphic 
and metabolizes a significant portion of clinically used 
drugs [16, 17]. The involvement of CYP 2D6 metabolism 
with other drug classes could be problematic for pri-
maquine because of the potential for CYP 2D6-mediated 
drug–drug interactions [18, 19].
Selective serotonin reuptake inhibitors (SSRIs) and 
selective serotonin and norepinephrine reuptake inhibi-
tors (SNRIs) have been used effectively for the treat-
ment of major depressive disorders, anxiety disorders, 
hot flashes, and post-traumatic stress disorder (PTSD) 
[20]. They have also been extensively characterized in 
regard to CYP 2D6 inhibition and drug–drug interac-
tions. These classes of antidepressants are relevant to the 
general public, military service members, and travellers 
for the treatment of the various conditions listed above 
[21]. The interactions between primaquine and SSRI/
SNRIs in this context have never been investigated with 
regard to the effect on primaquine metabolism. This is of 
interest because the SSRI and SNRI classes of antidepres-
sant drugs have been extensively characterized for their 
potential to interact/inhibit CYP 2D6 both in  vivo and 
in  vitro (see Table  1 for a list of SSRI/SNRI CYP inter-
actions) [22]. The thorough characterization of CYP 
2D6-SSRI/SNRI interactions makes these molecules a 
good model chemical series for primaquine DDI inter-
action studies [22]. In previous reports, SSRI/SNRI inhi-
bition of human CYP 2D6 has led to significant clinical 
alterations in pharmacokinetics/pharmacodynamics of 
co-prescribed drugs that are CYP 2D6 substrates [23, 24]. 
In that regard, the SSRI/SNRI antidepressants were used 
as tools in examining the impact of CYP 2D6-mediated 
DDIs in the context of primaquine pharmacology. Such 
analysis has been done with other drugs that are metabo-
lized by CYP 2D6. An example is the anti-cancer drug, 
tamoxifen. Metabolism of tamoxifen by CYP 2D6 to its 
active metabolite (endoxifen) was altered by co-medica-
tion with paroxetine [25, 26]. Since efficacy of primaquine 
has been linked with CYP 2D6 metabolism, drugs that 
inhibit CYP 2D6 (such as the SSRI/SNRIs) could result in 




Mixed-gender, pooled, cryopreserved, primary, human 
hepatocytes and cell culture reagents were purchased 
from BioreclamationIVT (Baltimore, MD, USA). The 
SSRI antidepressants (paroxetine, fluoxetine, fluvoxam-
ine, sertraline, citalopram, escitalopram), and SNRI anti-
depressants (venlafaxine, desvenlafaxine) were purchased 
from Sigma Aldrich (St Louis, MO, USA). Recombinant 
human CYP450 2D6 and the NADPH regeneration 
system solutions A and B were obtained from BD Bio-
sciences (San Jose, CA, USA).
IC50 determinations
Recombinant human CYP 2D6 metabolism of pri-
maquine was determined in the presence or absence of 
varying concentration of each antidepressant (0–100 μM) 
listed in the Table  1. Primaquine metabolism studies 
with human CYP 2D6 were conducted according to the 
manufacturer’s instructions. CYP 2D6 was pre-incubated 
with each corresponding antidepressant for 15 min prior 
to addition of primaquine. After primaquine addition 
(final concentration of 1 μM), aliquots were collected at 
0 and 60  min for primaquine incubations, followed by 
quenching with an equal volume of acetonitrile. Sixty-
minute incubations were chosen for IC50 determinations 
because of the robust primaquine metabolism signal 
observed on this timescale as previously reported (>80 % 
[27]). The samples were centrifuged at 15,700×g at 4  °C 
for 10 min, supernatants collected and analysed by liquid 
chromatography/tandem mass spectrometry (LC–MS/
MS). IC50 values were determined from plots of per cent 
primaquine remaining against antidepressant concentra-
tions. GraphPad (La Jolla, CA, USA) Prism 6 software 
was used for data analysis and graph plotting.
Metabolism studies with CYP 2D6 and inhibition 
via fluoxetine
Metabolism studies with recombinant human CYP 
2D6 were conducted according to the manufacturer’s 
instructions. Briefly, 10  μl of fluoxetine stock solution 
(stock-1  mM in DMSO) was mixed with the NADPH 
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regeneration system buffers A (50 μl) and B (10 μl). Thirty 
microlitre of CYP 2D6 isoenzyme and 0.1 M phosphate 
buffer (pH 7.4) was added to bring the volume in each 
well to 960 μl. The solution was gently mixed by pipetting 
and incubated at 37 °C for 15 min. Ten microlitre of pri-
maquine was then added to each well and the plate incu-
bated at 37  °C for the duration of the experiment. The 
final primaquine and fluoxetine concentrations were 1 
and 10 μM, respectively. Aliquots were collected at 0, 15, 
30 and 60 min, followed by quenching with an equal vol-
ume of acetonitrile. The samples were vortexed for 30 s, 
and centrifuged at 15,700×g at 4 °C for 10 min. Superna-
tant was collected and immediately analysed by LC–MS/
MS.
Primary human hepatocyte culture
Cryopreserved, pooled, human, primary hepatocytes 
were flash thawed in a 37  °C bath for 1 min. One vial of 
the thawed hepatocytes (5 million cells/vial) was added 
to 40  ml of pre-warmed thawing buffer, mixed thor-
oughly by gentle pipetting, and centrifuged at 72×g for 
6 min. The supernatant was then aspirated and the pel-
let resuspended in hepatocyte incubation buffer (InVit-
roGRO HI media, BioreclamationIVT, Baltimore, MD, 
USA). The hepatocytes were then seeded onto 12-well 
culture plates, approximately 7  ×  105 hepatocytes/ml 
per well, and incubated in a humidified 5 % CO2/95 % air 
incubator for 30 min prior to the addition of compounds.
Metabolism studies with pooled hepatocytes
Primaquine metabolism with primary, human, hepato-
cyte culture was conducted according to the methods 
published by Jin et  al. [5]. Antidepressant compounds 
(final concentration of 10  μM) were pre-incubated with 
hepatocyte culture plates for 15  min prior to treat-
ment with primaquine at 37  °C. Following the addition 
of primaquine (final concentration of 1  μM), aliquots 
(150 μl) were collected at 0 and 240 min; 240-min incuba-
tions were chosen for hepatocyte studies because of the 
robust primaquine metabolism signal observed on this 
timescale as previously reported (~40  % [5]). All reac-
tions were stopped by adding an equal volume of acetoni-
trile. Samples were thoroughly mixed by vortexing and 
centrifuged at 15,700×g at 4  °C for 10  min. The super-
natant was collected and 200 μl of sample was loaded on 
to a 96-well LC–MS/MS plate for analysis. Samples were 
analysed immediately after sample collection.
Analysis by LC–MS/MS
Analyte peaks were detected and quantified using a TSQ 
Quantum triple quadrupole mass spectrometer (Thermo 
Fisher Scientific, Waltham, MA, USA). Mass spectrometry 
conditions were optimized for each analyte (see Additional 
file  1 for masses and ion transitions). Chromatographic 
separations were achieved using a Waters XTerra MS C18 
(2.1 × 50 mm, 3.5 μm) column (Milford, MA, USA) with 
a Phenomenex (4 × 20 mm, 3.5 µm) guard column (Tor-
rance, CA, USA) at a flow rate of 0.35 ml/min. A 7-min lin-
ear gradient from 5 to 95 % acetonitrile (0.1 % formic acid) 
was utilized. Samples were analysed with electrospray ion-
ization in positive ion mode (source temperature 350 °C) 
by selected reaction monitoring at a collision pressure of 
1.0 mTorr. Analyte peaks were detected and quantified 
using the Xcalibur software package.
Pharmacokinetic measurements
All primaquine pharmacokinetic measurements were 
conducted as previously described in [14, 28]. Briefly, 
male, 9–12-weeks old, wild-type, C57BL/6 mice (Taconic 
Biosciences, Germantown, NY, USA) were used for phar-
macokinetic evaluations. On arrival, animals were accli-
mated for 7 days in quarantine. The animals were housed 
Table 1 List of antidepressants utilized in this study
Shown are the enzymes responsible for metabolism of each antidepressant, and enzymes each that each molecule inhibits. Table was adapted from [22]
Antidepressant Enzymes involved in biotransformation Enzymes inhibited by antidepressant
Citalopram CYP2C19, CYP2D6, and CYP3A4 CYP2D6 (weak)
Escitalopram CYP2C19, CYP2D6, and CYP3A4 CYP2D6 (weak)
Fluoxetine CYP2D6, CYP2C9, CYP2C19, and CYP3A4 CYP2D6 (strong), CYP2C9 (moderate), CYP2C19, (weak to moderate), CYP3A4 
(weak to moderate), CYP1A2 (weak)
Fluvoxamine CYP1A2 and CYP2D6 CYP2D6 (weak), CYP1A2 (strong), CYP2C19 (strong), CYP2C9 (moderate), CYP3A4 
(moderate)
Paroxetine CYP2D6 and CYP3A4 CYP2D6 (strong), CYP1A2 (weak), CYP2C9 (weak), CYP2C19 (weak), CYP3A4 (weak)
Sertraline CYP2C9, CYP2C19, CYP2D6, and CYP3A4 CYP2D6 (weak to moderate), CYP1A2 (weak), CYP2C9 (weak), CYP2C19 (weak), 
CYP3A4 (weak)
Venlafaxine CYP2D6 and CYP3A4 CYP2D6 (weak)
Desvenlafaxine CYP3A4 CYP3A4 (weak)
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in a cage maintained at a temperature range of 18–26 °C, 
34–68  % relative humidity and a 12-h light/dark cycle. 
Food and water were provided ad  libitum during quar-
antine and throughout the study. The animals were fed a 
standard rodent maintenance diet.
Pharmacokinetic studies were performed using oral 
administration. For primaquine dosing alone, three male 
C57BL/6 mice were dosed with primaquine at 20 mg/kg. 
The 20-mg/kg dose was chosen for this study because it 
has been extensively characterized previously in mice [14, 
29]. For the primaquine + fluoxetine, mice received three 
doses of fluoxetine (4 mg/kg/day) for 3 days. The mouse 
fluoxetine dose of 4 mg/kg was chosen as this corresponds 
to the human equivalent of 20 mg tablets per day based 
on body surface area (0.32 mg/kg in humans). This dose 
has been shown to be safe and effective for fluoxetine in 
clinical trials. On the third day, primaquine (20  mg/kg) 
was co-administered with the last fluoxetine dose. The 
multiple day dosing regimen was chosen to reflect the 
repeated daily dosing of antidepressants in humans. Both 
primaquine and fluoxetine were reconstituted in water, 
and administered at 5  μl/g. For each timepoint, animals 
were euthanized and plasma and liver samples collected. 
Plasma was obtained from whole blood (500 μl) collected 
by cardiac puncture. Five-hundred microlitre of 1000 
USP units/mL heparin (Hospira, Lake Forest, IL, USA) 
was added to whole blood samples to prevent coagula-
tion prior to plasma isolation via centrifugation. Isolated 
plasma samples were stored at −80  °C until LC–MS/
MS analysis. Liver samples were extracted from mice for 
each timepoint and immediately preserved on dry ice and 
stored at −80  °C until homogenization, extraction and 
LC–MS/MS analysis. Liver samples were resuspended 
using a sixfold dilution of ddH20 (w/v) and homogenized 
by sonication. Liver samples were then extracted (1:1 v/v) 
with acetonitrile. The samples were vortexed for 30 s, and 
centrifuged at 15,700×g at 4  °C for 10  min. Supernatant 
was collected and analysed by LC–MS/MS analyses.
Primaquine anti‑malarial efficacy experiments
Primaquine anti-malarial efficacy experiments were 
essentially conducted as described in [27, 29]. Briefly, oral 
primaquine and fluoxetine suspension solutions were pre-
pared in ddH20. Primaquine was dosed (20  mg/kg/day) 
using a three consecutive day treatment regimen (−1, 0, 
+1 day relative to infection). For the fluoxetine co-admin-
istration experiment, fluoxetine was dosed (4  mg/kg/
day) 2 days prior and on every day of primaquine admin-
istration (i.e., −3, −2, −1, 0, +1 day relative to infection). 
Drug suspensions were made and transferred to a 20-ml 
bottle, drawn into a 1-ml syringe, and delivered via oral 
feeder (18 gauge) to the designated recipient. The Plasmo-
dium berghei sporozoites used for inoculation (luciferase 
expressing) were obtained from laboratory-reared female 
Anopheles stephensi mosquitoes from Department of Mos-
quito Biology, Walter Reed Army Institute of Research, as 
described in [29]. Both liver and blood stages of P. berghei 
infections were monitored using the in vivo imaging sys-
tem (IVIS) and flow cytometry as described in [29].
Results
Inhibition of CYP 2D6 mediated metabolism of primaquine 
by SSRI/SNRI drugs in vitro
Eight commercially available antidepressants were utilized 
to test the drug–drug interactions with primaquine. The 
antidepressants from the SSRI and SNRI classes chosen 
are shown in Table 1 (fluoxetine, paroxetine, fluvoxamine, 
sertraline, escitalopram, citalopram, venlafaxine, desvenla-
faxine). The inhibitory potency of SSRI/SNRI compounds 
on CYP 2D6-mediated metabolism of primaquine were 
examined in  vitro. Primaquine metabolism by recombi-
nant CYP 2D6 isoenzyme was monitored after 60  min 
in the absence or presence of increasing concentrations 
of each SSRI/SNRI compound. SSRI/SNRI compounds 
were incubated with CYP 2D6 prior to primaquine addi-
tion. The results are shown in Fig. 1 as relative per cent of 
primaquine remaining after 60 min as a function of SSRI/
SNRI compound concentration. The results illustrate that 
as the SSRI/SNRI concentrations increased, the relative 
per cent of primaquine remaining also increased suggest-
ing CYP 2D6 inhibition and a reduction of primaquine 
metabolism. The IC50 values for each SSRI/SNRI incuba-
tion were determined by fitting each titration curve and 
are indicated for each SSRI/SNRI compound above each 
graph. The most potent inhibitors were fluoxetine and par-
oxetine with corresponding IC50 values of 1.05 µM ± 0.21 
and 1.24 µM ± 0.11, respectively (Fig. 1a, b). The remain-
ing SSRI molecules (fluvoxamine, sertraline, escitalo-
pram, citalopram) had IC50 values of 2.05  µM  ±  1.28, 
4.35  µM  ±  0.48, 7.35  µM  ±  0.68 and 9.28  µM  ±  0.57, 
respectively (Fig.  1c–f). Primaquine metabolism was 
least affected by the SNRI compounds venlafaxine and 
desvenlafaxine IC50 values of 19.11  µM  ±  1.65 and 
94.28 µM ± 6.72, respectively (Fig. 1g, h).
Inhibition of CYP 2D6‑mediated metabolism of primaquine 
by SSRI/SNRI drugs in hepatocytes
Having established the inhibitory trends of the different 
SSRI/SNRI molecules using recombinant CYP 2D6, SSRI/
SNRI inhibition of primaquine metabolism was further 
assessed in primary human hepatocytes. Cell cultures 
were pre-treated with SSRI or SNRI drugs (10 µM) prior 
to primaquine incubations. Ten micrometre was chosen 
as a screening concentration to determine if each SSRI/
SNRI had an effect on primaquine metabolism in hepato-
cytes. Primaquine metabolism results in hepatocytes are 
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shown in Fig. 2. The relative per cent primaquine remain-
ing is shown at 0 h (grey bars) and after 4-h incubation 
with hepatocytes. SSRI/SNRI drugs used are indicated on 
the x-axis. Primaquine was metabolized when incubated 
with hepatocytes with no SSRI/SNRI pre-treatment, 
as only 60  % of the primaquine remained after incuba-
tion period (green bar). This value was therefore used 
to determine if pre-treatment with the indicated SSRI/
SNRI molecules caused inhibition of primaquine metab-
olism in the hepatocyte cultures when tested at 10  μM. 
The results for venlafaxine and desvenlafaxine indicated 
no inhibition of primaquine metabolism as primaquine 
levels after the 4-h incubation period were similar to the 
primaquine-hepatocyte only control. Pre-treatment of 
hepatocytes with the remaining antidepressant molecules 
resulted in decreased primaquine metabolism over the 
4-h incubation period. These results are consistent with 
recombinant enzyme data and indicate that primaquine 
interacts in vitro with antidepressants that are CYP 2D6 
inhibitors.
Pharmacological interactions between primaquine 
and fluoxetine
The results from the SSRI/SNRI IC50 determinations and 
hepatocyte experiments indicated that primaquine is 
likely prone to CYP 2D6-mediated drug–drug interac-
tions when incubated with CYP 2D6 inhibitors. While 
insightful, the translation into a pharmacological effect 
for primaquine with CYP 2D6 inhibitor co-adminis-
tration is currently unknown. The SSRI fluoxetine was 
chosen to investigate this as it was the most potent CYP 
2D6 inhibitor tested (IC50 = 1.05 µM). The pre-incuba-
tion of CYP 2D6 with fluoxetine completely inhibited 
primaquine metabolism in  vitro at 10  µM as shown in 
Fig. 3a. Fluoxetine is capable of reaching low micrometre 
concentrations in  vivo and has a long elimination half-
life [30]. Additionally, the major metabolite of fluoxetine 
(nor-fluoxetine) is also a potent CYP 2D6 inhibitor with 
a long elimination half-life. It was for these pharmaco-
logical reasons that fluoxetine was selected from the list 
of antidepressants to test and determine if co-admin-
istration with primaquine had any pharmacological 
effects.
The pharmacokinetics of primaquine and a CYP 
2D6-dependent primaquine metabolite (5,6-ortho-
quinone) were determined in mice with and without 
fluoxetine co-administration. Interestingly, the phar-
macokinetics of parent primaquine were not drasti-
cally altered by co-administration with fluoxetine (see 
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Fig. 1 Inhibitory effects of second‑generation antidepressants on primaquine metabolism by recombinant CYP2D6. The relative per cent pri‑
maquine remining after 60‑min incubations with CYP 2D6 vs antidepressent concentration is shown for each compound tested. Fluoxetine (a) and 
paroxetine (b) were the most potent inhibitors for CYP2D6‑mediated metabolism of primaquine, while desvenlafaxine (h) was the least potent. c–g 
are titration curves for the remaining antidepressants tested (fluvoxamine, sertraline, escitalopram, citalopram, venlafaxine). The determined IC50s are 
shown above each graph. The error shown is from duplicate experiments
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2D6-dependent metabolite (5,6-orthoquinone) were 
altered upon fluoxetine co-administration. The fluox-
etine-treated mice had lower 5,6-orthoquinone liver 
concentrations as indicated in Fig. 3b, presumably from 
reduced CYP 2D metabolism as a result of a fluoxetine/
CYP 2D-mediated drug–drug interaction. Reduced pro-
duction of the 5,6-orthoquinone primaquine metabo-
lite would imply that less of the active primaquine 
metabolite(s) would be produced in the fluoxetine-
treated mice and thus might alter the anti-malarial activ-
ity of primaquine.
To ascertain if fluoxetine co-administration with 
primaquine had any effect on anti-malarial activity, a 
malaria mouse model employing P. berghei parasites was 
used to assess primaquine efficacy. This model has been 
used previously to characterize primaquine anti-malarial 
activity in the context of differential CYP 2D6 metabo-
lism [27]. Primaquine was administered to mice at a ther-
apeutic dose (20 mg/kg/day for 3 days) with and without 
co-administration of fluoxetine (4 mg/kg/day for 5 days, 
see “Methods” section). Presence of P. berghei infection 
was monitored via IVIS signal and flow cytometry. Out 
of the three groups tested (infection control, primaquine 
treated, and primaquine  +  fluoxetine treated), only the 
infection control had a robust IVIS signal during the first 
72  h post infection. Blood stage parasitaemia measure-
ments are shown in Fig. 3c and survival in Fig. 3d. Blood 
stage parasitaemia was detected in all mice of the infec-
tion control group. In the control group, 0/5 mice sur-
vived to the end of the experiment (day 31, see survival 
plot in Fig. 3d). Cure of P. berghei infection was defined 
as parasitaemia-free throughout the duration of the 
31-day experiment. Three mice in the infection control 
group died on day 10 post inoculation and the remain-
ing two were euthanized on day 15 due to high parasitae-
mia measurements. The primaquine-treated group (blue 
line) had 5/5 mice survive the duration of the experiment 
parasitaemia-free. The primaquine  +  fluoxetine-treated 
group (red line) had only 1/5 animals survive the dura-
tion of the experiment. The four mice that did not survive 
were euthanized on day 17 post inoculation due to high 
parasitaemia measurements (>5 %). The results from the 
primaquine + fluoxetine-treated mice indicate that even 
though a dose of primaquine was given that has been 
shown to be therapeutic against P. berghi, that co-admin-
istration of fluoxetine negatively impacted primaquine 
efficacy. These results along with the in vitro metabolism 
data presented above likely indicate that primaquine anti-
malarial activity can be altered through CYP 2D6-medi-



























Fig. 2 Primaquine metabolism by primary human hepatocyte culture pretreated with antidepressants (SSRI or SNRI). Samples were analysed by 
LC–MS/MS for primaquine disappearance. The 0 and 4‑h incubation timepoint measurements for primaquine are shown for the controls and with 
each tested antidepressant. A relative per cent remaining value of <60 % for primaquine indicated no inhibition of metabolism (green bars) while a 
value of >60 % indicated inhibition by the indicated antidepressants (red bars). The error shown is from duplicate experiments
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Discussion
The in vitro metabolism and in vivo mouse results above 
indicate the potential for drug–drug interactions between 
primaquine and the SSRI/SNRI antidepressants. While 
these results are insightful and suggestive, the clinical 
implications of such interactions remain unknown due 
to the limitations in extrapolating clinical outcomes from 
in  vitro experiments and prophylactic mouse malaria 
models. In the study presented above, the in vivo effects 
of CYP 2D6-mediated DDIs with primaquine were only 
determined with fluoxetine at a fixed dose. Future studies 
using different CYP 2D6 inhibitors at different doses (to 
establish dose response correlations) are required to con-
firm that primaquine is susceptible to CYP 2D6-mediated 
DDIs. Controlled human clinical studies are ulti-
mately needed to assess the impact of primaquine DDI 
Fig. 3 Pharmacological interactions between primaquine and fluoxetine. a Fluoxetine‑mediated complete inhibition of primaquine metabolism 
by CYP 2D6 in vitro. Shown is the time course of primaquine CYP 2D6 metabolism alone (blue line), or upon fluoxetine pre‑treatment (red line). The 
error shown is from duplicate experiments. b Liver Cmax values from pharmacokinetic analysis of the CYP 2D6‑dependent primaquine metabolite 
5,6‑ortho‑quinone from mice given a single primaquine dose (20 mg/kg, blue bar), or mice given a single primaquine dose (20 mg/kg) with fluoxe‑
tine (12 mg/kg daily for 3 days, see “Methods” section, red bar). The error shown is from triplicate pharmacokinetic analyses. c Average per cent para‑
sitaemia measurements from flow cytometry measurement for the infection control group (black line), primaquine + fluoxetine (PQ + FLX)‑treated 
mice (red line), and primaquine alone ‑treated mice (PQ, blue line). d Anti‑malarial efficacy of primaquine in a prophylaxis mouse malaria model. The 
per cent survival of mice infected with P. berghei is shown for the different treatment groups. Mice infected and not given any anti‑malarial drug 
are shown by the black line (0/5 survived duration of experiment). Mice infected and given primaquine at the ED100 are shown by the blue line (5/5 
survived duration of experiment). Mice infected and given primaquine at the ED100 along with concurrent fluoxetine administration are shown by 
the red line (1/5 survived duration of experiment). Five mice were used per group for efficacy experiments
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interactions on anti-malarial efficacy as rodent malaria 
models are limited in that the antiparasitic activity of 
primaquine is only assessed for active hepatic schizonts 
and not dormant hypnozoites. The direct extrapolation 
of these results to human anti-malarial activity remains 
to be determined and warrants further investigation. In 
light of such limitations, it is interesting that the SSRI/
SNRI inhibitory effects on CYP 2D6-mediated pri-
maquine metabolism are similar to those measured using 
other CYP 2D6 probe substrates [31]. The IC50 values 
measured in vitro indicate the likelihood of primaquine-
SSRI interactions with the most potent CYP 2D6 inhibi-
tors (IC50 <2  μM, paroxetine and fluoxetine). SSRIs and 
other therapeutic agents (e.g., anti-malarial drugs that are 
also CYP 2D6 inhibitors) have been reported in the liter-
ature to have plasma concentrations in the mid-nanomo-
lar to low-micromolar range [32] and would likely have 
elevated concentrations in the liver tissue where inhibi-
tion of hepatic metabolism would occur. It is also inter-
esting to note that co-administration of fluoxetine with 
primaquine in the mouse malaria model did not com-
pletely inhibit the anti-malarial activity of primaquine. 
The primaquine–fluoxetine-treated group did not have 
detectable liver stage infection within the first 72 h of the 
experiment. Four out of five of these mice did have par-
asitaemia by day 8 post infection. Both the lack of IVIS 
signal within the first 72 h and delayed parasitaemia (in 
comparison to the infection control) for the primaquine–
fluoxetine-treated mice indicates that fluoxetine reduces 
the anti-malarial activity of primaquine, however, it does 
not completely abrogate it. This phenomenon is probably 
a result of partial inhibition of the mouse CYP 2D path-
way by fluoxetine. The effects of the primaquine–fluox-
etine interaction in humans would likely be even more 
complex as the extent of fluoxetine-mediated CYP 2D6 
inhibition would likely be different for the various human 
CYP 2D6 genotype/phenotypes.
Primaquine has been used for decades in the treatment 
of relapsing forms of malaria. Despite this, the mechanism 
of action for primaquine efficacy and clinical pharmacol-
ogy in the context of drug–drug interactions is not fully 
understood. The recent advances in primaquine pharma-
cology regarding the requirement for CYP 2D6-mediated 
activation provide a possible explanation for some of 
the observed drug–drug interactions reported in the lit-
erature for primaquine [33, 34]. The work conducted by 
Purittayakamee et al., Hanboonkunupakarn et al. and Jit-
tamala et  al. highlight observed drug–drug interactions 
in humans between primaquine and the co-administered 
anti-malarials: chloroquine, dihydroartemisinin-pipe-
raquine and pyronaridine-artesunate. All three combina-
tions resulted in significantly higher primaquine exposure 
as a result of likely interactions with shared metabolic 
pathways. The human clinical significance of these inter-
actions remains to be fully elucidated; it is interesting 
to note however these primaquine PK interactions in 
the context of the observed improved clinical outcomes 
reported for primaquine combination therapy back in 
1955 by Alving and colleagues [35]. These findings along 
with the recent pharmacokinetic studies and the work by 
Alving et al. highlight the complex nature of primaquine 
drug–drug interactions and indicate that more than CYP 
2D6 metabolism should be considered when interpret-
ing such studies. Other factors, such as modulation of 
transporters and other CYP-metabolizing enzymes (other 
than CYP 2D6) should be taken into consideration for 
future primaquine studies. The primaquine-SSRI/SNRI 
work presented above is no different in that there could 
be other metabolic pathways modulated by co-adminis-
tration of SSRI/SNRIs such as the CYP 3A4, 2C19 and/
or CYP 2C9 as indicated in Table  1. Ultimately, more 
clinical observations are required to elucidate the human 
pharmacological consequences of primaquine drug–drug 
interactions in the context of anti-malarial activity.
Conclusions
The worked presented above provides insight into 
potential drug–drug interactions with the anti-malarial 
drug primaquine. Additionally, this work brings to light 
another factor to consider when examining primaquine 
therapeutic failures. Successful primaquine therapy in 
humans seems to correlate with predicted CYP 2D6 
phenotype. CYP 2D6 poor and intermediate metaboliz-
ers are more likely to fail therapy [7, 15, 36]. Potent CYP 
2D6 inhibitors such as fluoxetine and other SSRI mol-
ecules have been shown using phenotypic analysis to sig-
nificantly alter CYP 2D6 activity. Alfaro et al. showed that 
fluoxetine administration changed the CYP 2D6 pheno-
type of human subjects from extensive to poor metaboliz-
ers based on dextromethorphan/dextrorphan phenotypic 
analysis [24]. Such significant alterations of CYP 2D6 
activity could have detrimental consequences for humans 
with vivax malaria undergoing primaquine therapy.
Additional file
Additional file 1. Reference compounds utilized in Primaquine pharma‑
cokinetic study. (A) The structures of Primaquine (PQ) and the marker for 
5‑hydroxylation (5,6‑ortho‑quinone) are shown. The liquid chromatogra‑
phy and mass spectrometry parameters utilized for quantitation of PQ and 
the phenolic metabolite. Shown are the observed m/z ions, product ms/
ms ions, cone voltages, collision energies, and electrospray polarities uti‑
lized for quantitation. Additionally, the retention times for each molecule 
are also indicated. Separate standard curves and analyses of PK samples 
were conducted for each analyte. (B) Liver pharmacokinetics of a single 
20 mg/kg dose of primaquine alone (blue line), or co‑administered with 
fluoxetine (red line). (C) Liver pharmacokinetics of the 5,6‑orthoquinone 
metabolite from a single 20 mg/kg dose of primaquine alone (blue line), 
or upon co‑administration with fluoxetine (red line).
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